Otros idiomas OPKO Health, Inc.

Acciones

OPK

US68375N1037

Tiempo real estimado Cboe BZX Otros sitios de cotización 17:43:19 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,295 ^USD	-0,38 %		+3,17 %	-13,91 %

28/03	Laboratory Corp of America adquirirá activos específicos del negocio de diagnóstico de BioReference	MT
20/03	Entera Bio anuncia datos farmacocinéticos sólidos para el primer tratamiento oral en tabletas de péptidos Glp-2 de su clase para pacientes con síndrome de intestino corto	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024	14:00
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations	01/04
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	28/03
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
OPKO Health : Immediate Report	15/03
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	14/03
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	13/03
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	12/03
OPKO Health - AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	06/03
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	05/03
OPKO Health : Immediate Report	02/03
OPKO Health : Report of Periodic or Interim Report	02/03
OPKO Health: Q4 Earnings Snapshot	27/02
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	27/02
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results	27/02
Drugmakers deepen efforts to tap into booming market for obesity drugs	27/02
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?	23/02
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024	22/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas OPKO Health, Inc.

Acciones

OPK

US68375N1037

Otros idiomas

Filtros